Table 1 Clinicopathological features of 79 bladder cancer patients and the expressions of circLIFR
From: CircLIFR synergizes with MSH2 to attenuate chemoresistance via MutSα/ATM-p73 axis in bladder cancer
| Parameters | Group | Cases | circLIFR expression | P value | |
|---|---|---|---|---|---|
| High | Low | ||||
| Gender | Male | 66 | 34 | 32 | 0.7695 |
| Female | 13 | 6 | 7 | ||
| Age at surgery | < 55 | 11 | 5 | 6 | 0.7555 |
| ≥55 | 68 | 35 | 33 | ||
| Pathological stage | pTa-T1 | 21 | 16 | 5 | 0.0100 |
| pT2-T4 | 58 | 24 | 34 | ||
| Lymph node metastasis | Absent | 69 | 37 | 32 | 0.1927 |
| Present | 10 | 3 | 7 | ||
| Vascular invasion | Absent | 72 | 36 | 36 | > 0.9999 |
| Present | 7 | 4 | 3 | ||
| Muscle invasion | NMIBC | 31 | 21 | 10 | 0.0210 |
| MIBC | 48 | 19 | 29 | ||
| Total | 79 | 40 | 39 | ||